Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration.
Minthon. L L; Edvinsson. L L; Ekman. R R; Gustafson. L L
Key Findings
- s disease (DAT).",
- ,
Practical Outcomes
- The results are mainly descriptive and do not suggest any new treatment or supplement protocol. For biohackers, the study only hints that DSIP might serve as a biomarker for different dementias, but there is no actionable guidance on using DSIP for health optimization.
Summary
A study measured three brain chemicals in the spinal fluid of people with two kinds of dementia. It found that the peptide called DSIP was lower in Alzheimer's disease but a bit higher in frontotemporal dementia. Other chemicals (somatostatin and neuropeptide Y) also changed differently between the two diseases.
Abstract
The CSF levels of somatostatin-LI (SLI), neuropeptide Y (NPY-LI) and Delta Sleep Inducing Peptide (DSIP-LI) have been measured in patients with dementia of Alzheimer type (DAT) and dementia with frontotemporal degeneration of non-Alzheimer type (FTD). The distribution pattern of cortical degeneration differs between these two types of dementia. DAT shows degeneration of mainly temporo-parietal and temporo-limbic structures, whereas FTD discloses its main degeneration in the frontotemporal regions (Brun, 1987). The somatostatin-LI was significantly reduced both in DAT and FTD. NPY-LI showed a significant reduction in DAT but not in FTD. A tendency to a reduction with duration of the disease was observed in DAT whereas the contrary was noted in FTD. The DSIP-LI levels were reduced in DAT and slightly increased in FTD. The study provides an evidence of neurochemical differences between the two primary degenerative dementias.
Study Information
pubmed
1990
10.1007/978-3-7091-3345-3_6
29
22